-
Dingbin Liu/Chen Xu of JEV Nankai University found that the identification of fecal extracellular vesicles can be used as a novel biomarker for the non-invasive diagnosis and prognosis of colorectal
Time of Update: 2023-02-03
Colorectal cancer (CRC) is one of the most common malignancies and is usually detected late in the clinic.
In conclusion, the study shows that fEV can be used as a novel biomarker in the diagnosis and prognosis of colorectal cancer in a completely non-invasive manner, with high clinical sensitivity and sensitivity, providing new opportunities for large-scale colorectal cancer screening.
-
The Slit2 signaling pathway stimulates the growth of Ewing's sarcoma
Time of Update: 2023-02-01
Their findings reveal a novel role in stimulating the growth of Ewing sarcoma by the Slit2 signaling pathway and suggest that the pathway can be targeted for therapy.
-
Common oral bacteria can cause pancreatic cancer to metastasize
Time of Update: 2022-10-25
Other cancer studies have confirmed the microbe's presence in pancreatic cancer, leading Verbridge and his team to wonder if the bacteria might also activate tumor migration in the pancreas.
-
A case of abnormally elevated white blood cells triggers thinking
Time of Update: 2022-10-25
Case studiesBased on the patient's history, peritoneal effusion may be due to decompensation of cirrhosis, hypoproteinemia, and portal hypertension; The patient himself has chânybronchiolitis with emphysema, which may cause elevated white blood cells in peripheral circulation, but not to a large extent.
-
JAMA Sub-journal: Beijing Tiantan Hospital: Comparison of general anesthesia or sedation in intravascular therapy in patients with posterior circulation ischemic stroke
Time of Update: 2022-10-12
To investigate whether sedation (CS) can replace general anesthesia (GA) in intravascular therapy in patients with acute posterior circulation stroke, a recent study was published in JAMA Neurology.
-
Mobozantinib is used in patients with positive EGFR exon 20 insertion mutations, significantly prolonging survival
Time of Update: 2022-10-12
EGFR (Epidermal Growth Factor Receptor) is no stranger to cancer patients and is the most common driver gene for non-small cell lung cancer, especially in up to 60% of lung adenocarcinomas. EGFR mutat
-
Quick check Staging of GASTRIC CANCER CT
Time of Update: 2022-09-30
Spiral CT staging of gastric cancer is the main technology of preoperative staging diagnosis of gastric cancer, and it is of great significance to guide the formulation of gastric cancer treatment pla
-
Expert consensus on the treatment of ESMOEGFR-mutated non-small cell lung cancer (2022
Time of Update: 2022-09-19
Consensus: Adjuvant chemotherapy is strongly recommended for surgically resected stage Ib-IIIa (7th TNM), EGFR-mutated, and good performance status NSCLC patients with or without targeted therapy .
Consensus: Adjuvant chemotherapy is strongly recommended for surgically resected stage Ib-IIIa (7th TNM), EGFR-mutated, and good performance status NSCLC patients with or without targeted therapy .
-
JCO: Can immunotherapy combined with T-VEC for advanced melanoma bring new hope
Time of Update: 2022-09-07
An international randomized, double-blind, multicenter study from J Clin Oncol showed that T-VEC-pembrolizumab did not significantly improve progression-free survival (PFS) compared with placebo-pembrolizumab.
An international randomized, double-blind, multicenter study from J Clin Oncol showed that T-VEC-pembrolizumab did not significantly improve progression-free survival (PFS) compared with placebo-pembrolizumab.
-
European Radiology: Application of AI-based automatic spleen segmentation in risk stratification of liver cancer patients with TACE
Time of Update: 2022-08-19
Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC.
Fully automated AI-based splenic segmentation for predicting survival and estimating the risk of hepatic decompensation in TACE patients with HCC.
-
European Radiology: Application of deep learning-based ultrasound nomogram model in preoperative prediction of pancreatic neuroendocrine tumor aggressiveness
Time of Update: 2022-08-19
Recently, published in European Radiology, combining CEUS image-based DL with clinical factors to develop and validate a combined nomogram model for personalized prediction of preoperative tumor aggressiveness in patients with PNENs for accurate preoperative risk profiling.
-
Accelerated approval of oncology drug withdrawals in 'acceleration
Time of Update: 2022-06-11
Among the 167 indications for accelerated approval of oncology drugs, 66 are undergoing confirmatory trials, 83 have been finalized and 83 have been approved by the FDA, and 18 have been withdrawn .
-
Two innovative therapies for the treatment of autoimmune diseases reach phase 3 clinical endpoints
Time of Update: 2022-05-08
argenx announced that its antibody therapy Vyvgart (efgartigimod alfa-fcab) targeting the neonatal Fc receptor (FcRn) met the primary endpoint in a Phase 3 clinical trial for the treatment of immune thrombocytopenia (ITP), comparable to placebo The proportion of patients who achieved sustained platelet remission was significantly higher .
-
Early ivermectin treatment fails to reduce COVID-19 hospitalizations
Time of Update: 2022-04-16
3% in the placebo group,There was one primary outcome event: COVID-19 hospitalization or worsening of COVID-19 in emergency department visits, defined as more than 6 hours of observation within 28 days after randomization; relative risk 0.
-
Yale Cancer Center study confirms treatment for aggressive bladder cancer
Time of Update: 2022-03-07
Image: ASCO GU 2022Source: Yale Cancer CenterA new study led by Yale Cancer Center researchers finds that enfortumab vedotin is effective in patients with muscle-invasive bladder cancer (MIBC) who are not eligible for cisplatin chemotherapy .
